An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle,Seunghee Kim-Schulze,Hsin-Hui Huang,Noam D. Beckmann,Sharon Nirenberg,Bo Wang,Yonit Lavin,Talia H. Swartz,Deepu Madduri,Aryeh Stock,Thomas U. Marron,Hui Xie,Manishkumar Patel,Kevin Tuballes,Oliver Van Oekelen,Adeeb Rahman,Patricia Kovatch,Judith A. Aberg,Eric Schadt,Sundar Jagannath,Madhu Mazumdar,Alexander W. Charney,Adolfo Firpo-Betancourt,Damodara Rao Mendu,Jeffrey Jhang,David Reich,Keith Sigel,Carlos Cordon-Cardo,Marc Feldmann,Samir Parekh,Miriam Merad,Sacha Gnjatic
DOI: https://doi.org/10.1038/s41591-020-1051-9
IF: 82.9
2020-08-24
Nature Medicine
Abstract:Several studies have revealed that the hyper-inflammatory response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity and death. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α and IL-1β in hospitalized patients with coronavirus disease 2019 (COVID-19) upon admission to the Mount Sinai Health System in New York. Patients (<i>n</i> = 1,484) were followed up to 41 d after admission (median, 8 d), and clinical information, laboratory test results and patient outcomes were collected. We found that high serum IL-6, IL-8 and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival (<i>P</i> < 0.0001, <i>P</i> = 0.0205 and <i>P</i> = 0.0140, respectively). Notably, when adjusting for disease severity, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death. These findings were validated in a second cohort of patients (<i>n</i> = 231). We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.
biochemistry & molecular biology,cell biology,medicine, research & experimental